## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.42 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($212.76)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Jump Financial LLC Buys New Shares in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251208T114452 | Bullish | Relevance: 100%
-  Jump Financial LLC has acquired a new stake in AbbVie Inc. (NYSE:ABBV) by purchasing 84,789 shares valued at approximately $15,739,000 during the second quarter. Other institutional investors also increased their holdings in AbbVie, which reported strong quarterly earnings and increased its dividend. The company also received several positive analyst ratings and price target increases.

**2. Ose Immunotherapeutics stock falls after AbbVie deal amendment By Investing.com**
- Source: Investing.com UK | 20251208T131948 | Neutral | Relevance: 100%
- Ose Immunotherapeutics' stock dropped 4.25% after amending its agreement with AbbVie, shifting more financial and developmental responsibility to Ose. Under the revised terms, Ose will now fund and conduct the Phase 1 study for their immunotherapy partnership, eliminating a previously anticipated milestone payment. While the overall deal value remains unchanged at $700 million, the market reacted negatively to Ose's increased financial burden and the removal of near-term payment certainty.

**3. SCS Capital Management LLC Increases Stock Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251206T170724 | Bullish | Relevance: 99%
-  SCS Capital Management LLC significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 39.6% in Q2, boosting its holdings to 24,578 shares valued at $4.56 million. AbbVie recently raised its quarterly dividend to $1.73, equating to an annualized $6.92 with a 3.1% yield, and reported strong Q3 earnings beating analyst estimates. The company maintains a "Moderate Buy" consensus rating with an average price target of $241.85.

**4. Federated Hermes Inc. Acquires 134,942 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251207T120752 | Bullish | Relevance: 99%
- Federated Hermes Inc. increased its holdings in AbbVie Inc. by 4.1% during the second quarter, purchasing an additional 134,942 shares and bringing its total stake to 3,418,332 shares valued at approximately $634.5 million. This makes AbbVie the fund's sixth-largest holding, representing about 1.2% of its portfolio. AbbVie recently reported strong earnings, exceeding analyst estimates with $1.86 EPS and $15.78 billion in revenue, and subsequently raised its quarterly dividend to $1.73 per share, resulting in an annual yield of roughly 3.1%.

**5. Stenger Family Office LLC Takes Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251206T180716 | Bullish | Relevance: 99%
- Stenger Family Office LLC has acquired a new stake of 14,787 shares in AbbVie Inc. (NYSE:ABBV) during the second quarter, valued at approximately $2.799 million. This move comes as AbbVie successfully beat Q3 earnings estimates with an EPS of $1.86 and revenue of $15.78 billion, also raising its quarterly dividend to $1.73 per share. Several analysts have updated their price targets and ratings on ABBV shares, with a consensus of "Moderate Buy" and an average target price of $241.85.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $394.3B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from -3.0% to -4.6% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.6pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.77), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.64% (CS: 18) | Weak |
| RSI_14 | 44.2 | Neutral |
| MACD Histogram | -0.77 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 1.090x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $223.12
- **Stop Loss:** $212.76 (4.6% risk)
- **Target:** $243.84 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $10,709.76
- **Portfolio %:** 10.71%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*